Aktuellt
SENASTE
The strategy is clear – to gradually phase out the BIP portfolio to instead find license partners for commercialisation, although we understand the sutures and wound care offering will be kept under own management as momentum seems strong and it is profitable. The licence setup is profitable and scalable (sales of concentrate and royalty based on net sales). This means potential is huge if Zimmer succeed in its categories and other deals show on top.
LÄS MER
